There is persistent immunosuppression not only in allogeneic but also in autologous stem cell transplantation because humoral and cellular immunity may take a year or more to return to normal, with increased risk of infectious complications. This immune defect may also involve antigen presentation, in particular dendritic cell (DC) function. We evaluated DC subset reconstitution in 58 patients who underwent bone marrow (BM) or peripheral blood (PB) autologous haematopoietic stem cell transplantation (HSCT). In all patients DC type 1 (DC1) and DC type 2 (DC2) were already significantly lower than in normal individuals before conditioning therapy (DC1/l 3.1 ؎ 1.0, DC2/l 3.0 ؎ 1.1). On day 0 and day ؉7 the mean DC1 and DC2 numbers were very low in both groups. Patients who received unmanipulated marrow or peripheral blood stem cells reached pre-conditioning levels of DC1 and DC2 cells on day ؉20. In patients receiving selected CD34 cells, DC increased slowly and pre-transplant counts were observed only on day ؉60. Nearly 'normal' levels of DC1 and DC2 could be observed in the first group from day ؉180, and were maintained thereafter; in CD34 ϩ selected patients DC1 and DC2 counts remained lower than normal. Our data emphasise that circulating antigen presenting cells (APC) recover quickly. It remains to be determined if DC frequency in PB reflects their tissue function. The relatively low incidence of infections in patients undergoing autologous transplantation, despite defective lymphocyte reconstitution, could be related to functionally efficient DC. Bone Marrow Transplantation (2002) 30, 261-266. doi:10.1038/sj.bmt.1703637 Keywords: dendritic cell; autologous stem cell transplantation; immunological recovery High-dose chemotherapy followed by haemopoietic stem cell transplantation (HSCT) is increasingly used for various
haematologic malignancies and solid tumours. It is now well-recognised that there is persistent immunosuppression not only in allogeneic but also in autologous stem cell transplantation because humoral and cellular immunity may take a year or more to return to normal, with increased risk of infectious complications. 1 Functional reconstitution of the lymphoid compartment after autologous bone marrow/ peripheral blood HSCT depends either on the presence of adequate numbers of antigen-specific T and B cells in the transplant or the maturation of lymphoid progenitors and perhaps multipotent stem cells into antigen-specific T and B cells within thymic and bone marrow microenvironments. The early post-transplant period is characterised by a reduction of CD4 + T cells (due to a persistently low level of naive CD4 + /CD45RA + T cells) and by elevated numbers of CD8
+ T cells. The number of B cells is also reduced. [2] [3] [4] [5] [6] [7] This immune defect may also involve antigen presentation. On this subject, it has been suggested that the patients' antigen presenting cells (APC) are abnormal either numerically or functionally after transplant. 8 Dendritic cells (DC) are the most powerful APC in inducing T cell activation. They originate from pluripotent stem cells in the bone marrow; then, they migrate from peripheral blood to tissues, where they achieve the capacity to capture and process antigens. In lymphoid organs DC present these processed antigens to and activate T cells. 9 Recently, two subsets of DC have been identified in peripheral blood. DC type 1 (lineage negative, HLA-DR positive and CD11c positive) are myeloid and activate (through interaction between CD80 and CD28, in the presence of IL-12) T helper type 1 (Th1), which produce IL-1 and IFN␥ (pro-inflammatory cytokines); DC type 2 (lineage negative, HLA-DR positive and CD123 positive) may be lymphoid and activate (through interaction between CD86 and CD28, in the presence of IL-10) T helper type 2 (Th2), which produce IL-4 and IL-10 (anti-inflammatory cytokines). 8, [10] [11] [12] In this paper we evaluated the kinetics of lymphocyte and dendritic cell subset reconstitution in 58 patients undergoing bone marrow or peripheral blood autologous HSCT and its relationship with infectious complications.
Patients and methods
The kinetics of lymphocyte and dendritic cell reconstitution were studied in 58 consecutive patients affected by NHL Bone Marrow Transplantation (n ϭ 28), HL (n ϭ 6), multiple myeloma (n ϭ 15), acute leukaemias (n ϭ 4) and breast cancer (n ϭ 5) who received intensification therapy and autologous stem cell rescue (HSCT) from January 1997 to December 2000. Patients with NHL received the BAVC (cytosine-arabinoside, etoposide, cyclophosphamide and carmustine) conditioning regimen, patients with HL received the BEAM (cytosinearabinoside, etoposide, melphalan and carmustine) conditioning regimen, myeloma patients received busulphan and melphalan, patients with acute leukemia received busulphan and cyclophosphamide and breast cancer patients received etoposide, carboplatinum and iphosphamide. A median of 2.6 ϫ 10 Table 1 .
Dendritic cell reconstitution
Dendritic cell recovery was evaluated before starting the conditioning regimen, at day 0 before stem cell infusion, at day ϩ7 and at the same points as lymphocytes. DC1 (CD11c ϩ , myeloid origin) and DC2 (CD123 ϩ , lymphoid origin) subsets were identified by using a three-colour flow cytometric assay on lysed whole blood to minimise selective loss. For each test 100 l of blood were incubated with 10 l of the HLA-DR-PerCP (BD), with 20 l of a mixture of lineage-related antibodies FITC (lineage cocktail 1 FITC, BD), including the following monoclonal antibodies: CD3, CD14, CD16, CD19, CD20 and CD56, and with 10 l of the CD11c-PE or the CD123-PE antibodies. At the end of a 15 min incubation, red cells were lysed as described above, samples were washed twice and immediately analysed. A minimum of 50 000 events was acquired for each experiment. Dendritic cells express high levels of HLA-DR and lack lineage-related antigens. After gating lineage-negative events, the two DC1 and DC2 subsets were identified in the high HLA-DR expressing population, on the basis of their high CD11c or CD123 intensity. Nega- 
Immune reconstitution
Peripheral blood lymphocyte subsets were analysed by flow cytometry before starting the conditioning regimen, at time 0, before stem cell infusion, at time ϩ30, ϩ60, ϩ90, ϩ240, ϩ360, ϩ3 years. One hundred l of peripheral blood anticoagulated with EDTA were incubated at laboratory temperature for 20 min with the following monoclonal antibodies: CD3FITC, CD19PE, CD4PE, CD8FITC, CD16PE, CD56PE, CD45ROFITC, CD45RAFITC. At the end of incubation red cells were lysed by Facs Lysis solution (BD, Bruxelles, Belgium), washed twice and analysed within 1 h. Acquisition and analysis were performed with a FacsCalibur (BD) flow cytometer with Lysis II software. WBC cell counts were determined using an automated cell counter (CELL DYN 3200).
Total lymphocyte count was determined by flow cytometry by incubating a sample of whole blood with the CD14PE/CD45FITC (BD) antibodies. The absolute number of lymphocytes was calculated by multiplying the percentage of CD14 − /CD45 ϩϩ by the total WBC. The absolute number of cells in any given lymphocyte population was calculated by multiplying the percentage of positive cells for each lymphocyte marker by the absolute lymphocyte number. Data were expressed as mean number Ϯ 2 standard deviations per microliter of PB.
Normal controls
Circulating dendritic cell and lymphocyte subsets of 15 healthy donors were evaluated as described above, to obtain normal reference values.
Data analysis
Mean differences at different times between patients and normal controls were assessed by the Mann-Whitney U test.
Results
Transplant-related data are summarised in Tables 2 and 3 . Haematological recovery occurred promptly in all patients, without any differences between patients receiving bone marrow or peripheral blood stem cells. The median time to reach a neutrophil count >1 ϫ 10 9 /l was day ϩ10 (9) (10) (11) (12) (13) (14) in PB patients, day ϩ13 (11-15) in PB selected patients and day ϩ12 (10-30) in BM patients. The median time to reach a platelet count >20 ϫ 10 9 /l was day ϩ11 (9-30), day ϩ14 (10-21) and day ϩ12 (10-30), respectively. Not considering CD34
ϩ selected patients 23/46 (50%) had a febrile episode; only in 8/46 (17.3%) was a gram ϩ bacter- A stomatitis grade III-IV, was the most frequent toxic sideeffect (4/12 patients, 33.3%). No deaths occurred during the early post-transplant period (follow-up of 12 months). We did not test T helper 1 and T helper 2 cell functions on the basis of DC phenotype; we tested DC1 and DC2 in patients who had infection and we found, as expected, low levels of both.
Dendritic cell reconstitution
In all patients DC1 and DC2 cells were already significantly lower than in normal individuals before conditioning therapy (DC1 mean/l 3.1 Ϯ 1.0 vs mean 6.0 Ϯ 3.3 P ϭ 0.025, DC2 mean 3.0 Ϯ 1.1 vs 6.7 Ϯ 3.5 P ϭ 0.025). On day 0 before stem cell infusion, and on day ϩ7 the mean DC1 and DC2 number was very low (0.03 Ϯ 0.01 and 0.25 Ϯ 0.01 on day 0; 0.06 Ϯ 0.01 and 0.04 Ϯ 0.01/l on day ϩ7) in both groups (selected and not selected), but the recovery kinetics were quite different. As shown in Figures 1 and 2 , patients who received unmanipulated marrow or peripheral stem cells reached pre-conditioning levels of DC1 and DC2 cells at day ϩ30 (3.9 Ϯ 1.2 and 2.8 Ϯ 1.3, respectively). On the contrary, in patients receiving selected CD34 ϩ cells, dendritic cells increased slowly and pre-transplant counts were observed only on day ϩ60. No difference was observed in the kinetics of DC1 and DC2 reconstitution. Nearly 'normal' levels of DC1 and DC2 could be observed in the first group of patients from day ϩ180 (6.3 Ϯ 2.3 and 5.8 Ϯ 2.0), and were maintained thereafter (6.3 Ϯ 3.0 and 6.8 Ϯ 3.0 at 1 year; 7.3 Ϯ 3.3 and 6.6 Ϯ 3.0 at 3 years post transplant). In CD34 ϩ selected patients DC1 and DC2 counts were lower than normal up to 1 year post transplant (4.3 Ϯ 0.2 and 4.3 Ϯ 0.1, respectively). 
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Immune reconstitution
The B cell count (defined as the number of cells expressing the pan-B CD19 antigen) and the NK cell count (defined by the CD56 expression and the lack of CD3 antigen) rose to normal levels after 3 months post transplant in all patients. CD3 + cells rose to normal level after 3 years post transplant. CD8
+ cells rose over the normal level reaching a peak at day ϩ60 (811 Ϯ 150/l vs 557 Ϯ 78/l) and fell to normal levels within 6 months post transplant in the unselected group, and within 1 year in the selected group. CD4
+ lymphocytes remained less than 50% normal, so that all patients had a low CD4 + /CD8 + ratio (<1) over the first 6 months post transplant. In particular, the level of naive CD4 ϩ /CD45RA ϩ cells was persistently low in this period (at 6 months, mean 88 Ϯ 18/l vs 524 Ϯ 60/l in normal individuals, P ϭ 0.000). CD4 ϩ /CD45RO ϩ memory cells reached a plateau within the first 90 days post transplant and after that maintained this level (Figure 3) . 
Discussion
In the past years the availability of high stem cell numbers after peripheral blood mobilisation has extended the use of intensification regimens followed by autologous stem cell transplantation to very large series of haematological and non-haematological patients. The rapid haematological recovery has significantly reduced mortality during the transplant period, but a delay in lymphocyte recovery has been described, and is possibly responsible for long-term defects in immune reactivity involving both cellular and humoral arms of the immune response. [1] [2] [3] [4] [5] [6] [7] The reduced immune reactivity after stem cell transplantation could also be explained by defective antigen presentation involving dendritic cells. With the aim of better understanding the kinetics of post-transplant immune reconstitution we have evaluated dendritic cell recovery in 58 patients who underwent stem cell transplantation with unmanipulated peripheral blood or bone marrow stem cells or with highly purified, positively selected, CD34
+ cells. A group of 15 normal donors was employed as a reference population. Very little data on normal dendritic cell frequency in the peripheral blood are available. Fearnley et al 13, 14 developed a flow cytometric method suitable for routine evaluation of peripheral blood DC concentrations by using the monoclonal antibody CMRF44. By applying this method on 103 normal individuals they found counts ranging between 3 and 17 ϫ 10 6 /l. No difference was found on segregating the reference population by sex and age. However it must be emphasised that they used, as the reference marker, an activation antigen whose intensity of expression could be influenced by the culture system. Savary et al 15 17 evaluated DC1 and DC2 subsets in peripheral blood of normal stem cell donors finding values overlapping ours. Our patients, studied before transplant, showed significantly lower DC levels in the blood than healthy volunteers, probably as a consequence of previous chemotherapy. However our unpublished data on peripheral blood DC obtained in patients with haematological malignancies during staging procedures, show that low concentrations of both blood dendritic subsets are already detectable at the onset of the disease. It remains to be determined if this is an intrinsic patient characteristic, able to weaken the immune response to malignancies, or the effect of the higher blood efflux as a consequence of recruitment into the tumour. Different to what is observed in the conventional allogeneic setting (our data submitted for publication), at the end of the conditioning regimen (day 0) and at day ϩ7 low concentrations of dendritic cells could be detected, perhaps as an effect of the less myeloablative conditioning regimen. The persistence of host dendritic cells can play an important role in inducing tolerance and chimerism when a non-myeloablative regimen is used for allogeneic transplantation. In our series of patients dendritic cell recovery, at the pre-transplant level, occurred nearly as promptly as the haematological recovery, but is delayed in myeloma patients receiving highly purified CD34 ϩ cells. In this cohort of patients pretransplant counts are reached only 3 months after transplantation and normal levels were never observed. Analogously, Savary et al 15 found uniformly low DC concentrations in breast cancer patients 1-5 months after stem cell transplantation. Conversely Fearnley et al 14 could not point out differences among patients according to graft source or CD34 selection, also observing a complete DC recovery 60 days after autograft. Likewise Galy et al 16 obtained normal DC levels at day 42 post-CD34 selected transplantation. Different previous treatment regimens and mobilisation protocols, CD34 enrichment procedures (Isolex vs CliniMacs), different degrees of bone marrow infiltration and finally higher Bone Marrow Transplantation age can contribute to explaining the delayed recovery in our myeloma group. DC1/DC2 ratio was close to 1 at each time in both groups suggesting that CD34 −dim dendritic precursors are lost by the selection procedure, but equal lymphoid and myeloid dendritic potential is maintained by the residual stem cell pool.
In conclusion, as previously reported by several authors, [1] [2] [3] [4] [5] [6] [7] our data confirm the delayed post-transplant immune recovery, in particular concerning 'naive' CD4 lymphocytes, but emphasise that circulating antigen presenting cells are quickly recovered. It remains to be determined if DC frequency in peripheral blood reflects their tissue function. Shiobara et al 18 showed that defects in Ig secretion after allogeneic bone marrow grafting are due primarily to defective T and B cell function and that the monocyte accessory function is intact in most patients studied. So the relative low infections incidence in patients undergoing autologous transplantation, despite the defective lymphocyte reconstitution, could be related to the presence of functionally efficient DC.
